24.85%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 24.85 | 52.82 | 2.23 | 7.22 | 8.57 |
| Classification | 16.41 | 37.20 | -0.77 | 3.55 | 6.13 |
| Index (S&P 500) | 23.50 | 48.80 | -5.90 | 0.70 | -0.90 |
| % Rank in Class (1-best,100=worst) | 22 | 14 | 11 | 11 | 21 |
| Investment Objective: | Health/Biotech |
|---|---|
| Net Assets ($Mil) | 1,929.90 |
| Inception Date: | 12/29/95 |
| Manager Name, Tenure | Kris H. Jenner, 2000 |
| Expense Ratio: | 0.86% |
|
Sales Charge:
Load Type:
|
No Load 0.00% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Gilead Sciences Inc | GILD | 5.55 |
| Alexion Pharm | ALXN | 3.79 |
| Baxter International Inc | BAX | 3.26 |
| Medco Health Sol | MHS | 2.72 |
| Roche Holding Ag | RHHVF | 2.52 |
| Teva Pharmaceutical Industries Ltd | TEVA | 2.44 |
| Express Scripts Inc | ESRX | 2.38 |
| Henry Schein | HSIC | 2.34 |
| Amgen | AMGN | 1.98 |
| Vertex Pharma | VRTX | 1.84 |
| % of Total Holdings | 28.82 | |